STOCK TITAN

Inozyme Pharma, Inc. - $INZY STOCK NEWS

Welcome to our dedicated page for Inozyme Pharma news (Ticker: $INZY), a resource for investors and traders seeking the latest updates and insights on Inozyme Pharma stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Inozyme Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Inozyme Pharma's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.54%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.26%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.6%
Tags
none
Inozyme Pharma, Inc.

Nasdaq:INZY

INZY Rankings

INZY Stock Data

293.20M
34.13M
0.66%
92.95%
4.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BOSTON

About INZY

we are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. our area of expertise is in disorders of paradoxical mineralization and our lead drug is an enzyme replacement therapy in pre-clinical development.